Tesaro nabs a Merck cancer drug for its pipeline

Forbes reports that Tesaro--a 2011 Fierce 15 company--has just in-licensed the cancer drug niraparib from Merck ($MRK). The therapy fits into a new class of cancer drugs called PARP inhibitors, with potential to treat ovarian and breast cancers. A number of Big Pharma companies have been spinning off programs that no longer fit within their revised pipeline strategies. And Tesaro, which was launched by a group of veterans from MGI Pharma, thinks it can benefit from the trend. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.